The sizzling antibody-drug conjugate (ADC) field is at the center of another major life sciences deal. This time, AbbVie is shelling out $10.1 billion in cash to acquire ImmunoGen, maker of the ...

AbbVie is set to acquire ImmunoGen for $10.1 billion, gaining Elahere, a promising ovarian cancer treatment, and enhancing its oncology portfolio. ImmunoGen's advanced ADC pipeline, including ...

AbbVie has agreed to acquire ImmunoGen for $10.1 billion, the companies said today, in a deal designed to add long-term revenue growth to the buyer’s oncology franchise by accelerating its entry into ...

An antigen is any substance that can trigger an immune response in the body. Antigens are typically proteins or polysaccharides that are recognized as foreign or potentially harmful by the immune ...